Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 9/20 | 1.00 |
| ▸ | MMP2 | P08253 | 9/20 | 1.00 |
| ▸ | MMP9 | P14780 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.79 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247434 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL30080242 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL247433 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL1595342 | 0.88 | KMT2A (1.00) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL29388461 | 0.88 | KMT2A (1.00) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL296015 | 0.88 | KMT2A (1.00) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL13675628 | 0.86 | TRPV1 (1.00) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL8061581 | 0.86 | MMP1 (0.75) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL8061578 | 0.86 | MMP1 (0.75) | MMP1MMP2MMP9MAPTKMT2A | |
| SCHEMBL6275866 | 0.85 | MMP1 (0.73) | MMP1MMP2MMP9MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776408-B | Preparation method of 7-hydroxy-2-quinolinone | 上海医药工业研究院 | 2022-12-20 | — | — | CN | disclosed |
| EP-3397636-B1 | PROCESS FOR THE PREPARATION OF QUINOLINE-2(1H)-ONE DERIVATIVES | HONOUR R&D (IN) | 2021-08-04 | — | — | EP | disclosed |
| US-20210207175-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-07-08 | — | — | US | disclosed |
| WO-2019238091-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2019-12-19 | — | — | WO | disclosed |
| US-10464931-B2 | Process for the preparation of Quinolin-2(1H)-one derivatives | HONOUR (R&D) (IN) | 2019-11-05 | — | — | US | disclosed |
| US-20190010145-A1 | PROCESS FOR THE PREPARATION OF QUINOLIN-2(IH)-ONE DERIVATIVES | HONOUR (R&D) (IN) | 2019-01-10 | — | — | US | disclosed |
| EP-3397636-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE-2(1H)-ONE DERIVATIVES | Honour (R&D) (IN) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017115287-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE-2(1H)-ONE DERIVATIVES | HONOUR (R&D) (IN) | 2017-07-06 | — | — | WO | disclosed |
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2925762-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Sunovion Pharmaceuticals Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20080103154-A1 | 3, 4-dihydro-2(IH)-quinolinone and 2(1H)-quinolinone derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103154-A1 | 3, 4-dihydro-2(IH)-quinolinone and 2(1H)-quinolinone derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2002002108-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | MMP1 4851/4885MMP2 4587/4885MMP9 4776/4885 |
| US-20080103154-A1 | 3, 4-dihydro-2(IH)-quinolinone and 2(1H)-quinolinone derivatives | SLC6A3, HTR2C, AQP4 | MMP1 1636/4885MMP2 3795/4885MMP9 4423/4885 |
| US-10464931-B2 | Process for the preparation of Quinolin-2(1H)-one derivatives | UGT1A1, CYP1A2, CYP1A1 | MMP1 4713/4885MMP2 4218/4885MMP9 4259/4885 |
| US-20190010145-A1 | PROCESS FOR THE PREPARATION OF QUINOLIN-2(IH)-ONE DERIVATIVES | UGT1A1, CYP1A2, SDHA | MMP1 3903/4885MMP2 4149/4885MMP9 4531/4885 |
| US-20210207175-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | TET2, ZFX, ZFR | MMP1 4552/4885MMP2 3182/4885MMP9 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.